Affordable Access

deepdyve-link
Publisher Website

Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.

Authors
  • G, Vinothkumar1
  • S, Krishnakumar2
  • Sureshkumar3
  • G, Shivashekar4
  • S, Sreedhar2
  • Preethikrishnan5
  • S, Dinesh5
  • A, Sundaram1
  • D, Balakrishnan1
  • Riya5
  • P, Venkataraman6
  • 1 Department of Medical Research, SRM Medical college Hospital, SRM University, Chennai, India. , (India)
  • 2 Department of Nephrology, SRM Medical college Hospital, SRM University, Chennai, India. , (India)
  • 3 Department of Neurology, Balaji Medical college Hospital, Chrompet, Chennai, India. , (India)
  • 4 Department of Pathology, SRM Medical college Hospital, SRM University, Chennai, India. , (India)
  • 5 Department of Clinical Psychology, SRM Medical college Hospital, SRM University, Chennai, India. , (India)
  • 6 Department of Medical Research, SRM Medical college Hospital, SRM University, Chennai, India. Electronic address: [email protected] , (India)
Type
Published Article
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Publication Date
May 14, 2018
Volume
104
Pages
211–222
Identifiers
DOI: 10.1016/j.biopha.2018.05.028
PMID: 29775888
Source
Medline
Keywords
License
Unknown

Abstract

This study demonstrated that rHuEPO is an effective neuroprotective agent in the context of CKD associated cognitive dysfunction and proved its clinical usefulness.

Report this publication

Statistics

Seen <100 times